On December 30, 2025 XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported it has amended its collaboration, originally established in 2006, with Takeda through a strategic royalty share transaction. Takeda’s royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced, and XOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of nine development-stage assets that are held within Takeda’s externalized assets portfolio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to find ways to expand and diversify our royalty and milestone portfolio through creative transactions that are beneficial to both parties," stated Brad Sitko, Chief Investment Officer of XOMA Royalty. "Takeda and XOMA Royalty have a long history of collaboration. By amending our collaboration, we are able to return a portion of our mezagitamab economics to Takeda, while also expanding and diversifying XOMA Royalty’s portfolio across several interesting early- and late-stage programs."

Mezagitamab
Prior to amending the collaboration, XOMA Royalty held a mid-single digit royalty and $16.25 million in potential milestones associated with mezagitamab. Going forward, XOMA Royalty will retain a low single-digit royalty entitlement on mezagitamab and up to $13.0 million in milestones.

Development-Stage Assets from Takeda’s Externalized Assets Portfolio

Osavampator

Neurocrine Biosciences is developing osavampator, a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) for patients who have inadequate response to treatment for major depressive disorder (MDD).
Volixibat

Mirum Pharmaceuticals is developing volixibat, a minimally absorbed, orally administered investigational therapy designed to selectively inhibit ileal bile acid transporter (IBAT), for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).
OHB-607 and five early-stage Oak Hill Bio assets

Oak Hill Bio and their partner are developing OHB-607, a recombinant human IGF-1/IGFBP-3 for the prevention of bronchopulmonary dysplasia in premature infants. Additional Oak Hill Bio assets that have the potential to generate royalties address other high unmet need or rare disease areas.
REC-4881

Recursion Pharmaceuticals is developing REC-4881, an investigational MEK1/2 inhibitor for familial adenomatous polyposis, a rare tumor predisposition syndrome affecting approximately 50,000 people in the U.S., France, Germany, Italy, Spain, and the UK.

(Press release, Xoma, DEC 30, 2025, View Source [SID1234661659])

On December 30, 2025 Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, reported successfull listing on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on the Hong Kong stock market in 2025. With an issue price of HK$ 24.05 per share, Insilico Medicine opened at HK$35.00 per share, representing a market capitalization of approximately HK$ 19.51 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Qiming Venture Partners is one of Insilico Medicine’s most important institutional investors. Qiming Venture Partners led the Company’s Series B financing round in 2019 and continued its support in subsequent Series C and D rounds, with an about 7 percent stake in Insilico Medicine before its IPO.

Founded in 2014, Insilico Medicine employs a business model based on the Pharma.AI platform, focuses on internal drug research and development through artificial intelligence. It has gradually expanded the application of Pharma. AI to more industries such as advanced materials, agriculture, nutritional products, and veterinary drugs. It has now efficiently built a pipeline portfolio covering over 30 innovative projects in a wide range of fields with extensive demands, such as oncology, immunology, fibrosis, and metabolism, and owns the world’s most advanced first-in-class AI-based drugs.

To date, 13 of the world’s top 20 pharmaceutical companies by revenue have entered into software platform collaborations with Insilico Medicine. Insilico Medicine has also reached licensing agreements on three pipelines with global drugmakers such as Exelixis and Menarini, bringing a potential revenue of USD2 billion for the company. The Company has also established drug R&D partnerships with other internationally renowned pharmaceutical firms including Sanofi, Lilly, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

"Insilico is dedicated to extending human productive longevity and this listing provides us with more resources to advance our mission. Over the past few years, we set very clear industry benchmarks demonstrating that AI can help make drug discovery faster, cheaper, and deliver higher success rates in preclinical and early clinical development. We have validated the end-to-end capabilities of AI-empowered programs from novel target discovery to molecular generation, and then to preclinical and clinical stages. Going forward, we will continue to increase investment in our AI platform and innovative pipeline, accelerate the advancement of differentiated innovative programs into clinic, and bring truly accessible, affordable, and breakthrough treatment solutions to patients worldwide." said Alex Zhavoronkov, PhD, Founder and CEO, Chief Business Officer of Insilico Medicine.

"We invest in Insilico Medicine based on a simple belief that ‘AI will profoundly change the pathway and efficiency of drug development.’ We decided to invest in Insilico Medicine in 2019 because of its research in frontier areas when generative AI was not yet popularized. Now the value of Insilico Medicine in the field of AI pharmaceuticals is gradually being realized through preclinical validation and pipeline licensing. We expect AI to not only empower early-stage research and development but also effectively accelerate the clinical stage process in the future to enable new drugs to benefit patients earlier," Dr. Chen Kan, Partner and Healthcare Co-Lead at Qiming Venture Partners, said.

(Press release, Insilico Medicine, DEC 30, 2025, View Source [SID1234661660])

On December 30, 2025 GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, reported that Per Langoe, Chief Executive Officer of GT Medical Technologies, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026, at 4:00 PM PT in San Francisco, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to be presenting at the J.P.Morgan Healthcare Conference, reflecting the impact GammaTile has made in 2025 and the strong momentum we carry into 2026," said Per Langoe. "GammaTile continues to show strong clinical outcomes and evidence that are challenging the status quo for operable brain tumors. In addition, I am excited to share how the execution of our commercial strategies and programs, combined with strong revenue growth and enhanced operations support will allow for an increasingly scalable business model."

(Press release, GT Medical Technologies, DEC 30, 2025, View Source [SID1234661661])

On December 29, 2025 Genmab A/S (Nasdaq: GMAB) reported that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina‑S), which are advancing in late‑stage development. This decision is consistent with Genmab’s disciplined portfolio prioritization and capital allocation framework.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"After careful consideration, we have decided to discontinue the acasunlimab program. Although the data have been encouraging, the compelling opportunities we see in our late‑stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders. We are highly energized by the momentum of EPKINLY, petosemtamab and Rina‑S, and we remain committed to executing these programs with speed and rigor," said Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab.

This decision does not impact Genmab’s full‑year 2025 financial guidance.

(Press release, Genmab, DEC 29, 2025, View Source [SID1234661638])

On December 29, 2025 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) reported that the New Drug Application ("NDA") for fanregratinib (HMPL-453) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma ("ICC") with fibroblast growth factor receptor ("FGFR") 2 fusion/rearrangement who have previously received systemic therapy has been accepted and granted priority review by the China National Medical Products Administration ("NMPA").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fanregratinib (HMPL‑453) is a novel, selective, oral inhibitor targeting FGFR 1/2/3. ICC is a highly aggressive malignancy arising from the intrahepatic biliary epithelium. It accounts for 8.2-15.0% of primary liver cancers, and consequently it is the second most common type after hepatocellular carcinoma. In recent years, the incidence of ICC has continued to rise, with a 5-year overall survival rate of approximately 9%.[1] Approximately 10-15% of ICC patients globally have tumors harboring FGFR2 fusions or rearrangements.

This NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China. The study has met its primary endpoint of objective response rate (ORR). Results from the secondary endpoints including progression-free survival (PFS), disease control rate (DCR), duration of response (DoR) and overall survival (OS) also support the primary endpoint findings. Full results will be submitted for presentation at an upcoming scientific conference. Additional details may be found at clinicaltrials.gov using identifier NCT04353375.

About Fanregratinib
Fanregratinib (HMPL‑453) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. HUTCHMED currently retain all rights to fanregratinib worldwide.

(Press release, Hutchison China MediTech, DEC 29, 2025, View Source [SID1234661639])